EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial

Jing Zhang, Peng Wang iD, Yin Ren, Li Chen, Jin Feng, Fei Liu, Kaiwen Deng, Zhaoshi Bao, Xiaoguang Qiu iD, Yanwei Liu

Cancer · 2025

DOI: 10.1002/cncr.70171 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Cancer, 2025. Verfasst von Jing Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Temozolomide, Telomerase, Isocitrate Dehydrogenase, Glioma. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The long‐term results confirmed that the OS and PFS benefits from the RT‐TMZ exceeded those of the RT alone in patients with IDH‐wt/pTERTmut gliomas with tolerable toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomideTelomeraseIsocitrate DehydrogenaseGliomaChemoradiotherapyBrain NeoplasmsHumansFemaleMaleMiddle AgedAdultMutationPromoter Regions, GeneticRetrospective StudiesAgedNeoplasm GradingProspective StudiesYoung Adult

Stichwörter der Autor:innen

IDH wildtypeTERT mutationchemoradiotherapygliomaradiotherapy

Substanzen

TemozolomideTelomeraseTERT protein, humanIsocitrate DehydrogenaseIDH1 protein, human

Autor:innen und Institutionen

  • Department of Radiation Oncology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing, China.
  • Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
  • National Clinical Research Center for Neurological Diseases, Beijing, China.

ORCID-Profile: Peng Wang, Xiaoguang Qiu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Zhang, J., Wang, P., Ren, Y., Chen, L., Feng, J., Liu, F., Deng, K., Bao, Z., Qiu, X., & Liu, Y. (2025). Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. Cancer. https://doi.org/10.1002/cncr.70171

Vancouver

Zhang J, Wang P, Ren Y, Chen L, Feng J, Liu F, et al. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial. Cancer. 2025. doi:10.1002/cncr.70171

BibTeX
@article{Zhang2025,
  author = {Zhang, Jing and Wang, Peng and Ren, Yin and Chen, Li and Feng, Jin and Liu, Fei and Deng, Kaiwen and Bao, Zhaoshi and Qiu, Xiaoguang and Liu, Yanwei},
  title = {Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild‐type and TERT promoter mutation histological grade 2/3 gliomas: An extension retrospective analysis of a randomized controlled trial},
  journal = {Cancer},
  year = {2025},
  doi = {10.1002/cncr.70171}
}
Kostenlos starten →